Promising Developments and Strategic Trials Propel Kairos Pharma’s Buy Rating

Jason McCarthy, an analyst from Maxim Group, reiterated the Buy rating on Kairos Pharma, Ltd. (KAPA – Research Report). The associated price target remains the same with $4.00.

Jason McCarthy has given his Buy rating due to a combination of factors surrounding Kairos Pharma’s promising developments in their clinical trials. The company recently completed the safety lead-in arm of their Phase 2 trial for ENV-105 in patients with metastatic castration-resistant prostate cancer, which is a significant milestone. The trial aims to evaluate the efficacy of ENV-105 in combination with Erleada compared to Erleada alone, with progression-free survival as the primary endpoint.
Additionally, ENV-105 is a novel antibody targeting CD105, a protein involved in tumor angiogenesis and drug resistance. This innovative approach has the potential to re-sensitize tumors to standard-of-care therapies, which could significantly extend patient progression-free survival. The anticipated interim data in the second quarter of 2025 could act as a major catalyst for the stock, reinforcing the Buy recommendation. Furthermore, the valuation model considers potential commercialization and applies risk adjustments and discount rates, supporting a 12-month price target of $4.00.